C-reactive protein and tumor necrosis factor-alpha in relation to insulin-mediated glucose uptake, smoking and atherosclerosis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 7, 2008, Pages 534-541

  Fagerberg, Bjorn ^a,b   Behre, Carl Johan ^a,b   Wikstrand, John ^b   Hulten, Lillemor Mattsson ^b   Hulthe, Johannes ^b,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Atherosclerosis; C reactive protein; Dyslipidemia; Insulin resistance; Interleukin 6; Tumor necrosis factor alpha; Ultrasound

Indexed keywords

C REACTIVE PROTEIN; FAT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY FAT; CAROTID ARTERY; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMORAL ARTERY; GLUCOSE INFUSION; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHESIS; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAMPLE; SMOKING;

ATHEROSCLEROSIS; C-REACTIVE PROTEIN; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55249122741     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701870898     Document Type: Article

References (46)

1. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000;321:199-204.
2. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-18.
3. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999;100:96-102.
4. Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000;21:1000-8.
5. Hulthe J, Wikstrand J, Fagerberg B. Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study. Clin Sci (Lond) 2001;100:371-8.
6. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999;19:1986-91.
7. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997;17:2167-76.
8. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J 1996;312:1061-5.
9. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
10. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-7.
11. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.
12. Stephens JM, Butts MD, Pekala PH. Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-alpha. J Mol Endocrinol 1992;9:61-72.
13. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
14. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
15. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction - a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
16. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.
17. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994;94:1543-9.
18. Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994;5:207-15.
19. Kawakami M, Pekala PH, Lane MD, Cerami A. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA 1982;79:912-16.
20. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992;52:4113-16.
21. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253-78.
22. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384-9.
23. Bokemark L, Wikstrand J, Attvall S, Hulthe J, Wedel H, Fagerberg B. Insulin resistance and intima-media thickness in the carotid and femoral arteries of clinically healthy 58-year-old men. The Atherosclerosis and Insulin Resistance Study (AIR). J Intern Med 2001;249:59-67.
24. Sjöström LLL, Chowdhury B, Grangård U, Lissner L, Sjöström D, et al. The sagittal diameter is a valid marker of the visceral adipose tissue volume. In: Angel AAH, Bouchard C, Lau D, Leiter L, Mendelson R, editors. Progress in obesity research: 7. London: John Libbey & Company Ltd; 1996. p. 309-19.
25. Bokemark L, Froden A, Attvall S, Wikstrand J, Fagerberg B. The euglycemic hyperinsulinemic clamp examination: variability and reproducibility. Scand J Clin Lab Invest 2000;60:27-36.
26. Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb 1993;13:1404-11.
27. Wendelhag I, Liang Q, Gustavsson T, Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke 1997;28:2195-200.
28. Schmidt C, Wendelhag I. How can the variability in ultrasound measurement of intima-media thickness be reduced? Studies of interobserver variability in carotid and femoral arteries. Clin Physiol 1999;19:45-55.
29. Hulthe J, Wiklund O, Olsson G, Fagerberg B, Bokemark L, Nivall S, et al. Computerized measurement of LDL particle size in human serum. Reproducibility studies and evaluation of LDL particle size in relation to metabolic variables and the occurrence of atherosclerosis. Scand J Clin Lab Invest 1999;59:649-61.
30. Wahlefeld AW. Triglycerides: determination after enzymatic hydrolysis. In: Bergmeyer HU, editor. Methods of enzymatic analysis. 2nd English edn. New York: Academic Press.
31. Borner K, Klose S. [Enzymatic determination of total cholesterol with the Greiner selective analyzer (GSA-II) (author's transl)]. J Clin Chem Clin Biochem 1977;15:121-30.
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
33. Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994;236:567-73.
34. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-9.
35. Folsom AR, Pankow JS, Tracy RP, Arnett DK, Peacock JM, Hong Y, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001;88:112-7.
36. Sitzer M, Markus HS, Mendall MA, Liehr R, Knorr U, Steinmetz H. C-reactive protein and carotid intimal medial thickness in a community population. J Cardiovasc Risk 2002;9:97-103.
37. van der Meer IM, de Maat MP, Bots ML, Breteler MM, Meijer J, Kiliaan AJ, et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2002;22:838-42.
38. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
39. Fernandez-Real JM, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998;47:1757-62.
40. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997;46:451-5.
41. Fagerberg B, Hulthe J, Bokemark L, Wikstrand J. Low-density lipoprotein particle size, insulin resistance, and proinsulin in a population sample of 58-year-old men. Metabolism 2001;50:120-4.
42. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001;21:968-70.
43. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, et al. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:859-62.
44. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001;9:414-7.
45. Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997;78:273-7.
46. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 2000;85:1340-4.